---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042270"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:08:47.289943+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%

## Summary
- Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.
- Q2 product gross margin 55.6% vs 28.3% YoY; FY25 guidance reaffirmed ($8-10M revenue).
- Filed 510(k) for OneRF Trigeminal Nerve Ablation System for facial pain ahead of schedule; potential revenue in late CY2025.
- Raised $8.2M net in oversubscribed institutional offering in April; cash $9.4M post-raise; debt-free.
- Hired Dr. Parag Patil as Chief Medical Advisor and Emily Johns as General Counsel.

## SEC filing metadata
- accession: 0001213900-25-042270
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025042270/0001213900-25-042270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025042270/ea0241742-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042270
- JSON: https://secwatch.observer/filing/0001213900-25-042270.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.